GlaxoSmithKline CEO Emma Walmsley has reportedly received a pay cut of 14 per cent after the company missed an internal profit target for sales of routine vaccinations against other diseases.
According the pharmaceutical giant’s annual report, Ms Walmsley’s total remuneration for 2020 came in at seven million pounds (€8.2 million).
The cut, according to comments by Non-Executive Director Urs Rohner in the report, partly reflected a missed internal profit target for biopharmaceuticals, mainly due to lockdowns stopping people from receiving routine vaccinations which cut into the CEO’s bonus.
Ms Walmsley was appointed CEO in 2017, and has made great strides in the company’s restructuring efforts, as it works to split its consumer and pharmaceutical businesses.
GlaxoSmithKline has been among the frontrunners in the effort to develop COVID-19 vaccines and treatments, with the company’s offering, which was developed in conjunction with the University of Oxford, having been approved for use in over 50 countries.
Last month, pharmaceutical chiefs came under fire as EU leaders prioritised the acceleration of COVID-19 vaccination rollouts, with pharmaceutical companies being pressed to abide by delivery commitments.
Turks and Caicos marks ‘important step’ in growth, says Corinthia Group CEO
This development on Grace Bay in Turks and Caicos is in partnership with Carolina Partners Ltd.
MACM President Charles Xuereb urges companies to report payment defaults as uncertainty increases
His comments come as the Malta Association for Credit Management marks its 25th anniversary.
GTA 6 fever hits the workplace: Maltese employees are already booking launch day off
Rockstar Games’ long-awaited title is set for release on 19th November 2026.
Neriku unveils a new identity for its next chapter
The new positioning moves the brand towards a more contemporary, experience-led approach.
